BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hasskarl J, Kaufmann M, Schmid HA. Somatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors. Future Oncology 2011;7:895-913. [DOI: 10.2217/fon.11.66] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Zou Y, Tan H, Zhao Y, Zhou Y, Cao L. Expression and selective activation of somatostatin receptor subtypes induces cell cycle arrest in cancer cells. Oncol Lett 2019;17:1723-31. [PMID: 30675231 DOI: 10.3892/ol.2018.9773] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
2 Lambertini C, Barzaghi-Rinaudo P, D'Amato L, Schulz S, Nuciforo P, Schmid HA. Evaluation of somatostatin receptor subtype expression in human neuroendocrine tumors using two sets of new monoclonal antibodies. Regul Pept 2013;187:35-41. [PMID: 24188818 DOI: 10.1016/j.regpep.2013.10.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
3 Ito T, Fujimori N, Honma Y, Kudo A, Hijioka S, Katsushima S, Kimura Y, Fukutomi A, Hisamatsu S, Nakajima A, Shimatsu A. Long-term safety and efficacy of lanreotide autogel in Japanese patients with neuroendocrine tumors: Final results of a phase II open-label extension study. Asia Pac J Clin Oncol 2021;17:e153-61. [PMID: 32757459 DOI: 10.1111/ajco.13371] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
4 Moody TW, Ramos-Alvarez I, Jensen RT. Neuropeptide G Protein-Coupled Receptors as Oncotargets. Front Endocrinol (Lausanne) 2018;9:345. [PMID: 30008698 DOI: 10.3389/fendo.2018.00345] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
5 Perry JK, Liu D, Wu Z, Zhu T, Lobie PE. Growth hormone and cancer: an update on progress. Current Opinion in Endocrinology & Diabetes and Obesity 2013;20:307-13. [DOI: 10.1097/med.0b013e328363183a] [Cited by in Crossref: 43] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
6 Eychenne R, Bouvry C, Bourgeois M, Loyer P, Benoist E, Lepareur N. Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy. Molecules 2020;25:E4012. [PMID: 32887456 DOI: 10.3390/molecules25174012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
7 Li Q, You C, Liu L, Rao Z, Sima X, Zhou L, Xu J. Craniopharyngioma cell growth is promoted by growth hormone (GH) and is inhibited by tamoxifen: involvement of growth hormone receptor (GHR) and IGF-1 receptor (IGF-1R). J Clin Neurosci 2013;20:153-7. [PMID: 23117141 DOI: 10.1016/j.jocn.2012.04.014] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
8 Chalabi M, Duluc C, Caron P, Vezzosi D, Guillermet-guibert J, Pyronnet S, Bousquet C. Somatostatin analogs: does pharmacology impact antitumor efficacy? Trends in Endocrinology & Metabolism 2014;25:115-27. [DOI: 10.1016/j.tem.2013.11.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.8] [Reference Citation Analysis]
9 Hijioka S, Morizane C, Ikeda M, Ishii H, Okusaka T, Furuse J. Current status of medical treatment for gastroenteropancreatic neuroendocrine neoplasms and future perspectives. Jpn J Clin Oncol 2021;51:1185-96. [PMID: 34038547 DOI: 10.1093/jjco/hyab076] [Reference Citation Analysis]
10 Lesma G, Cecchi R, Cagnotto A, Gobbi M, Meneghetti F, Musolino M, Sacchetti A, Silvani A. Tetrahydro-β-carboline-based spirocyclic lactam as type II' β-turn: application to the synthesis and biological evaluation of somatostatine mimetics. J Org Chem 2013;78:2600-10. [PMID: 23409740 DOI: 10.1021/jo302737j] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
11 Rai U, Thrimawithana TR, Valery C, Young SA. Therapeutic uses of somatostatin and its analogues: Current view and potential applications. Pharmacol Ther 2015;152:98-110. [PMID: 25956467 DOI: 10.1016/j.pharmthera.2015.05.007] [Cited by in Crossref: 67] [Cited by in F6Publishing: 60] [Article Influence: 9.6] [Reference Citation Analysis]
12 Costanzi E, Simioni C, Conti I, Laface I, Varano G, Brenna C, Neri LM. Two neuroendocrine G protein-coupled receptor molecules, somatostatin and melatonin: Physiology of signal transduction and therapeutic perspectives. J Cell Physiol 2021;236:2505-18. [PMID: 32989768 DOI: 10.1002/jcp.30062] [Reference Citation Analysis]
13 Beglinger C, Hu K, Wang Y, Bouillaud E, Darstein C, Wang Y, Mohideen P. Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I study. Endocrine 2012;42:366-74. [DOI: 10.1007/s12020-012-9668-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
14 Stueven AK, Kayser A, Wetz C, Amthauer H, Wree A, Tacke F, Wiedenmann B, Roderburg C, Jann H. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future. Int J Mol Sci 2019;20:E3049. [PMID: 31234481 DOI: 10.3390/ijms20123049] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 9.3] [Reference Citation Analysis]
15 Selek A, Cetinarslan B, Canturk Z, Tarkun I, Hanazay Y, Vural C, Anik I, Ceylan S. The effect of somatostatin analogues on Ki-67 levels in GH-secreting adenomas. Growth Horm IGF Res 2019;45:1-5. [PMID: 30731342 DOI: 10.1016/j.ghir.2019.01.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
16 Ito T, Honma Y, Hijioka S, Kudo A, Fukutomi A, Nozaki A, Kimura Y, Motoi F, Isayama H, Komoto I, Hisamatsu S, Nakajima A, Shimatsu A. Phase II study of lanreotide autogel in Japanese patients with unresectable or metastatic well-differentiated neuroendocrine tumors. Invest New Drugs 2017;35:499-508. [PMID: 28470558 DOI: 10.1007/s10637-017-0466-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
17 Ferone D. Italian Society of Endocrinology Career Award Lecture: from somatostatin to…somatomedin. J Endocrinol Invest 2012;35:869-74. [PMID: 22932163 DOI: 10.3275/8583] [Reference Citation Analysis]
18 Pivonello C, De Martino MC, Negri M, Cuomo G, Cariati F, Izzo F, Colao A, Pivonello R. The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets. Infect Agent Cancer 2014;9:27. [PMID: 25225571 DOI: 10.1186/1750-9378-9-27] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
19 Klungboonkrong V, Das D, McLennan G. Molecular Mechanisms and Targets of Therapy for Hepatocellular Carcinoma. J Vasc Interv Radiol 2017;28:949-55. [PMID: 28416267 DOI: 10.1016/j.jvir.2017.03.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
20 . Current world literature. Curr Opin Endocrinol Diabetes Obes 2012;19:328-37. [PMID: 22760515 DOI: 10.1097/MED.0b013e3283567080] [Reference Citation Analysis]
21 Gao J, Tong H, Huang Z, Liu R, Li X, Qiang O, Tang C. Affinity analysis of somatostatin and somatostatin receptor by surface plasmon resonance. Anal Methods 2013;5:3201. [DOI: 10.1039/c3ay26548j] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
22 Li J, Guo B, Wang J, Cheng X, Xu Y, Sang J. Ovarian cancer G protein coupled receptor 1 suppresses cell migration of MCF7 breast cancer cells via a Gα12/13-Rho-Rac1 pathway. J Mol Signal 2013;8:6. [PMID: 23663350 DOI: 10.1186/1750-2187-8-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
23 Wu W, Zhou Y, Wang Y, Liu L, Lou J, Deng Y, Zhao P, Shao A. Clinical Significance of Somatostatin Receptor (SSTR) 2 in Meningioma. Front Oncol 2020;10:1633. [PMID: 33014821 DOI: 10.3389/fonc.2020.01633] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Gatto F, Barbieri F, Arvigo M, Thellung S, Amarù J, Albertelli M, Ferone D, Florio T. Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms. Int J Mol Sci 2019;20:E3940. [PMID: 31412614 DOI: 10.3390/ijms20163940] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]